“Allogeneic CAR-T cells are of increasing interest to many Pharma and BioPharma companies involved in cell-based cancer immunotherapies.
Almost 50 New Zealanders with neuroendocrine cancer are currently raising tens of thousands of dollars to pay for treatment in Australia because the life-prolonging treatment isn't available here. Tamaki MP and chair of Parliament's health committee ...
No comments:
Post a Comment